Syros Pharmaceuticals (NASDAQ:SYRS) Rating Increased to Hold at BidaskClub

BidaskClub upgraded shares of Syros Pharmaceuticals (NASDAQ:SYRS) from a sell rating to a hold rating in a research note released on Tuesday morning, BidAskClub reports.

A number of other equities research analysts have also weighed in on the stock. ValuEngine lowered shares of Syros Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday. JMP Securities lowered their price target on shares of Syros Pharmaceuticals from $18.00 to $16.00 and set a market outperform rating for the company in a report on Friday, October 18th. HC Wainwright reaffirmed a hold rating and set a $10.00 price target on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Piper Jaffray Companies lowered their price target on shares of Syros Pharmaceuticals from $24.00 to $18.00 in a report on Thursday, October 17th. Finally, Cowen reaffirmed a buy rating on shares of Syros Pharmaceuticals in a report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus price target of $13.46.

SYRS traded up $0.35 during trading hours on Tuesday, reaching $9.34. 37,810 shares of the stock traded hands, compared to its average volume of 327,048. The firm’s fifty day simple moving average is $6.12 and its two-hundred day simple moving average is $7.75. The company has a market cap of $350.98 million, a price-to-earnings ratio of -4.87 and a beta of 1.59. Syros Pharmaceuticals has a fifty-two week low of $4.45 and a fifty-two week high of $11.93. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.92 and a quick ratio of 4.92.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.01. The business had revenue of $0.56 million during the quarter, compared to analyst estimates of $0.43 million. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 84.49%. On average, research analysts predict that Syros Pharmaceuticals will post -1.88 earnings per share for the current year.

In related news, insider Jeremy P. Springhorn acquired 9,879 shares of Syros Pharmaceuticals stock in a transaction on Monday, November 11th. The shares were purchased at an average cost of $4.99 per share, for a total transaction of $49,296.21. Following the purchase, the insider now directly owns 24,879 shares of the company’s stock, valued at approximately $124,146.21. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 14.80% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of SYRS. Bank of Montreal Can lifted its position in shares of Syros Pharmaceuticals by 11,319.2% in the 2nd quarter. Bank of Montreal Can now owns 2,969 shares of the company’s stock worth $27,000 after buying an additional 2,943 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Syros Pharmaceuticals by 863.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,688 shares of the company’s stock worth $28,000 after buying an additional 2,409 shares during the last quarter. A.R.T. Advisors LLC bought a new position in shares of Syros Pharmaceuticals in the 2nd quarter worth about $119,000. Susquehanna International Group LLP bought a new position in shares of Syros Pharmaceuticals in the 2nd quarter worth about $133,000. Finally, Metropolitan Life Insurance Co NY bought a new position in shares of Syros Pharmaceuticals in the 3rd quarter worth about $138,000.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

Recommended Story: Price to Earnings Ratio (PE) Basics

Analyst Recommendations for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.